JAC Advance Access published online on September 14, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki335
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 College of Pharmacy, The University of Texas at Austin, 1 University Station Stop A1900, Austin, TX, USA 78712; Department of Pharmacology, The University of Texas Health Science Center at San Antonio, Clinical Pharmacy Programs-MSC 6220, 7703 Floyd Curl Dr., San Antonio, TX, USA 78229-3900; Department of Medicine, The University of Texas Health Science Center at San Antonio, Clinical Pharmacy Programs-MSC 6220, 7703 Floyd Curl Dr., San Antonio, TX, USA 78229-3900
* To whom correspondence should be addressed. Objectives: This study utilized pharmacokinetics/pharmacodynamics to compare Methods: Susceptibility data were extracted from the 2002 Intensive Care Unit Surveillance System (ISS) and pharmacokinetic parameters were obtained from published human studies. Monte Carlo simulation was used to model the free percent time above the MIC (free %T > MIC) for 18 Results: The 2002 ISS database contained MICs for 2408 Gram-negative isolates including 1430 Enterobacteriaceae, 799 P. aeruginosa, and 179 A. baumannii. Imipenem had the highest percentage susceptible for all Gram-negatives, Enterobacteriaceae and A. baumannii, while piperacillin/tazobactam had the highest percentage susceptible for P. aeruginosa. For empirical therapy, imipenem 0.5 g every 6 h, cefepime 2 g every 8 h and ceftazidime 2 g every 8 h demonstrated the highest CFR. For definitive therapy, imipenem 0.5 g every 6 h, ertapenem 1 g daily and cefepime 2 g every 8 h, cefepime 1 g every 8 h and cefepime 1 g every 12 h had the highest bactericidal CFR against Enterobacteriaceae; ceftazidime 2 g every 8 h, cefepime 2 g every 8 h, piperacillin/tazobactam 3.375 g every 4 h, ceftazidime 1 g every 8 h and aztreonam 1 g every 8 h against P. aeruginosa; and imipenem 0.5 g every 6 h, ticarcillin/clavulanate 3.1 g every 4 h, ceftazidime 2 g every 8 h, cefepime 2 g every 8 h and ticarcillin/clavulanate 3.1 g every 6 h against A. baumannii. Conclusions: Based on pharmacokinetics/pharmacodynamics, imipenem 0.5 g every 6 h, cefepime 2 g every 8 h and ceftazidime 2 g every 8 h should be the preferred
Received May 27, 2005
Revised August 19, 2005
Accepted August 24, 2005
Original article
Comparison of
-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics
2 College of Pharmacy, The University of Texas at Austin, 1 University Station Stop A1900, Austin, TX, USA 78712; Department of Pharmacology, The University of Texas Health Science Center at San Antonio, Clinical Pharmacy Programs-MSC 6220, 7703 Floyd Curl Dr., San Antonio, TX, USA 78229-3900
David S. Burgess, E-mail: BurgessD{at}uthscsa.edu
Abstract 
-lactam regimens for the empirical and definitive treatment of Gram-negative pulmonary infections in the ICU.-lactam regimens against all Gram-negative isolates, Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. The cumulative fraction of response (CFR) was determined for bacteriostatic and bactericidal targets (free %T > MIC): penicillins (
30/50%), cephalosporins/monobactams (40/70%) and carbapenems (20/40%).-lactam regimens for the empirical treatment of Gram-negative pulmonary infections in the ICU. The order of preference varied against Enterobacteriaceae, P. aeruginosa and A. baumannii.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Georges, J.-M. Conil, T. Seguin, S. Ruiz, V. Minville, P. Cougot, J.-F. Decun, H. Gonzalez, G. Houin, O. Fourcade, et al. Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4483 - 4489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Burgess and R. P. Rapp Bugs versus drugs: Addressing the pharmacist's challenge Am. J. Health Syst. Pharm., May 1, 2008; 65(9_Supplement_2): S4 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Frei, N. P. Wiederhold, and D. S. Burgess Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation J. Antimicrob. Chemother., March 1, 2008; 61(3): 621 - 628. [Abstract] [Full Text] [PDF]
|
|